Search clinical trials for: CP-870,893

Total 738 results

Abramson Cancer Center of the University of Pennsylvania

Completed

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Advanced Solid Tumors

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Solid Tumors

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Adenocarcinoma Pancreas

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Pfizer; Oncovir, Inc.

Completed

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Melanoma

United States
Hoffmann-La Roche

Completed

Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors

Neoplasms

United States
Brigham and Women's Hospital

Recruiting

CP101 for the Treatment of Ulcerative Colitis

Ulcerative Colitis

United States
Pfizer

Terminated

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

Obesity

United States, Australia, Canada, Brazil, Slovakia, Czech Republic, Argentina, Germany, Mexico, United Kingdom, Sweden
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis

Psoriasis

Japan
Siemens Molecular Imaging

Terminated

Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects

Breast Cancer

United States
Pfizer

Terminated

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

Obesity

Australia, United States, Korea, Republic of, Spain, France, United Kingdom, Germany, Sweden, Argentina, Chile, Mexico
Pfizer

Terminated

A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety

Obesity

United States, Canada
University of California, San Francisco
California Breast Cancer Research Program

Completed

Telephone-Based Decision Support for Rural Patients

Breast Cancer

United States
Institute for Clinical and Experimental Medicine

Recruiting

Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP (UNLOAD-AMI)

Myocardial Infarction | Shock, Cardiogenic | Remodeling, Ventricular

Czechia
Pfizer

Completed

ACTiF- Assessment of Closed Tibial Fractures

Tibial Fractures

United States, Australia, Canada, Spain, Turkey, Croatia, India, Bosnia and Herzegovina, Japan, Russian Federation, South Africa
Pfizer

Completed

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

Sarcoma, Ewing's

United States, United Kingdom
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Study of CP-461 in Patients With Advanced Renal Cell Cancer

Renal Cell Carcinoma

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Study Using CP-461 to Treat Advanced Prostate Cancer

Prostate Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Pfizer

Terminated

Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

Obesity

United States
Pfizer

Completed

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Dyslipidemia

United States
Azienda Usl di Bologna
Ministero della Salute, Italy

Recruiting

Connectivity in Cranioplasty

Ischemic Stroke | Traumatic Brain Injury | Acquired Brain Injury | Hemorrhagic Stroke

Italy
McMaster University

Completed

Community Paramedicine at Home (CP@Home)

Cardiovascular Disease | Diabetes Mellitus | Food Insecurity | Accidental Falls | Social Isolation

Canada
Pfizer

Completed

Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

Ewing's Sarcoma Family of Tumors

Spain, France, United States, Italy, Australia, Germany, United Kingdom, Israel, Canada, Brazil, Chile
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Unknown

CP-609,754 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Pfizer

Completed

CP-751,871 Treatment For Patients With Multiple Myeloma

Multiple Myeloma

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Terminated

CP-461 in the Treatment of Patients With Advanced Melanoma

Malignant Melanoma

United States
Pfizer

Completed

Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

Hepatic Insufficiency | Obesity

United States
Pfizer

Completed

Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

Obesity

United States
University of Colorado, Denver
National Cancer Institute (NCI)

Recruiting

Integrated Actionable Aging Assessment for Cancer Patients Pilot

Kidney Cancer | Leukemia | Myeloid Leukemia | Breast Cancer | Multiple Myeloma | Hodgkin Lymphoma | Prostate Cancer | Bladder Cancer | Lymphoid Leukemia | Monocytic Leukemia

United States
Centocor, Inc.

Completed

A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Taiwan, Korea, Republic of
Jonsson Comprehensive Cancer Center
Pfizer

Completed

CP-724,714 in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

CP-461 for the Treatment of Crohn's Disease

Crohn's Disease

United States
Pfizer

Terminated

A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer

Breast Neoplasms | Neoplasm Metastasis
Istituto Ortopedico Galeazzi

Recruiting

Patient Blood Management in the Approach to Prosthetic Surgery [PBM(L4178)] (PBM(L4178))

Anemia, Iron Deficiency

Italy
The University of Texas Health Science Center at...
Massachusetts General Hospital; 59th Medical Wing; Uniformed Services University... and other collaborators

Recruiting

Chronic Pain Management In Primary Care Using Behavioral Health Consultants

Chronic Pain

United States
Kaiser Permanente
Northwestern University; Duke University; Essentia Health; Georgia State University

Active, not recruiting

Tailored Non-Pharmacotherapy Services for Chronic Pain (RESOLVE)

Chronic Pain

United States
Yale University
National Center for Complementary and Integrative Health (NCCIH)

Active, not recruiting

Cooperative Pain Education and Self-management: Expanding Treatment for Real-world Access (COPES ExTRA) (COPES ExTRA)

Pain, Chronic

United States
Hugel

Terminated

the Hypertrophic Scar Prevention of BMT101.

Hypertrophic Scar

Korea, Republic of
The Hospital for Sick Children
C17 Council (regulatory sponsor)

Withdrawn

Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children (CONCOR-KIDS)

Covid-19 Infection | Hospitalized Children

Canada
Pfizer

Completed

Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers

Obesity

United States
Clavis Pharma

Completed

Clinical Study of Previously Untreated Patients With Malignant Melanoma

Neoplasm Metastasis | Malignant Melanoma

United States, Norway, Sweden
Pfizer

Terminated

A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

Stroke

United States, Italy, Spain, Singapore, Germany, Estonia, Portugal, Hungary
University of Arkansas
Tessenderlo Group

Not yet recruiting

Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing After Total Knee Arthroplasty (TKA)

Knee Osteoarthritis
Pfizer

Withdrawn

A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects

Healthy
Pfizer

Completed

The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.

Sexual Dysfunction, Physiological

Australia, Denmark, South Africa, Norway, Sweden
University of South Florida

Recruiting

Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation (Actigraphy)

Lung Diseases, Interstitial

United States
University of Leipzig
Jena University Hospital

Recruiting

Acute Impact of the Impella CP Assist Device in Pts. With Cardiogenic Shock on the Patients Hemodynamic (JenaMACS)

Cardiogenic Shock

Germany
University of Pennsylvania

Terminated

Impella CP With VA ECMO for Cardiogenic Shock (REVERSE)

Cardiogenic Shock

United States
Hacettepe University

Completed

International Classification of Functioning, Disability and Health and Lower Extremity Orthoses in Cerebral Palsy

Cerebral Palsy

Turkey

Search clinical trials for: CP-870,893

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations